Attendee search 

Oppifi Oy was founded in 2007. The business idea of Oppifi is to develop, promote and sell services for storing and sharing memories the life stories.

The main product of Oppifi is a “recollection and life story” service Epooq. The service assists users to recall and tell stories with the help of digital storytelling; video, voice, photo and text. Stories can be shared to the relevant social networks – communities – by your own choise.

The chain that connects generations is built from different life stories. These stories include a wealth of personal experience, insight and learning about life and living. Life experience creates the meaning for human life.

Epooq is targeted especially for the grandparent generation, which has a lot of life experience and the need to store and share that. It was chosen a winner in the 2011 World Summit Award competition.

Epooq is sold as a service for
• Nursing homes guided groups
• Individual use active living at home

Contact Information
Oppifi Oy
Ilkka Tiainen
ilkka.tiainen@oppi.fi
www.oppi.fi

FinnMedi Oy is a service provider for technology transfer, growth company business development, regulatory issues and clinical trials. We work closely with Life Science companies assisting them to search for new markets, private and public funding and collaboration partners for R&D and to set up clinical trials. For universities we provide technology transfer services.

Project Tide is commercializing novel respiration measurement technology developed at Tampere University of Technology. The first application of this technology platform is in DIAGNOSIS AND MANAGEMENT OF CHILDHOOD ASTHMA.

Because of the very limited methods for objective lung function measurement in young children their diagnostic procedures for asthma are currently based on qualitative and subjective estimates of the symptoms. Approximately 15 % of all children exhibit symptoms before school age. There have been technological attempts to solve this widely acknowledged problem, but none have been successful so far. Our approach is paradigm changing and will globally affect the course of pediatric asthma diagnosis and management.

Our innovative system enables lung function measurements with practically no need of co-operation from the child. The measurement is done over one 24h period and analysed for signs of asthma in the respiratory flow pattern.

The technology is currently in clinical trial phase with the leading pediatric asthma research group in Finland. The first phase results on asthmatic preschool children are very encouraging and will be published soon.

We are seeking seed funding to establish a company in Q2 / 2014.